A Phase 1b/2, Open-label, Multicenter Dose-ranging Trial to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of SRA737 in Combination With Niraparib in Subjects With Metastatic Castration-resistant Prostate Cancer

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 13 Jul 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Niraparib (Primary) ; SRA 737 (Primary)
Indications Adenocarcinoma; Prostate cancer
Focus Adverse reactions; Therapeutic Use
Sponsors Sierra Oncology

Most Recent Events

13 Jul 2020 Status changed from recruiting to discontinued.
20 May 2019 Status changed from planning to recruiting.
28 Feb 2019 According to a Sierra Oncology Inc. media release, the company is currently evaluating the optimal timing to commence this trial.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight